Spots Global Cancer Trial Database for childhood acute monoblastic leukemia (m5a)

Every month we try and update this database with for childhood acute monoblastic leukemia (m5a) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531	NCT01407757	Leukemia	DNA analysis gene expression... laboratory biom... pharmacogenomic...	- 29 Years	Children's Oncology Group
Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia	NCT01321385	Leukemia	laboratory biom... study of socioe...	- 21 Years	Children's Oncology Group
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia	NCT00003405	Leukemia	recombinant int... amifostine trih... bromodeoxyuridi... cytarabine idarubicin idoxuridine isotretinoin mitoxantrone hy...	0 Years - 70 Years	Rush University Medical Center
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome	NCT00002547	Leukemia Myelodysplastic...	busulfan cyclophosphamid... cyclosporine cytarabine methotrexate allogeneic bone... syngeneic bone ...	- 60 Years	Barbara Ann Karmanos Cancer Institute
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	NCT00002798	Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child...	asparaginase daunorubicin hy... fludarabine pho... therapeutic hyd... allogeneic bone... 3-dimensional c... filgrastim cytarabine idarubicin dexamethasone thioguanine etoposide methotrexate cyclophosphamid... aldesleukin busulfan	- 21 Years	National Cancer Institute (NCI)
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia	NCT00006363	Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... de Novo Myelody... Untreated Adult... Untreated Child...	cytarabine daunorubicin hy... etoposide valspodar filgrastim busulfan autologous hema... peripheral bloo... aldesleukin clinical observ... pharmacological...	15 Years - 59 Years	National Cancer Institute (NCI)
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia	NCT01076569	Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Child... Untreated Child...	laboratory biom...	- 21 Years	Children's Oncology Group
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia	NCT00003405	Leukemia	recombinant int... amifostine trih... bromodeoxyuridi... cytarabine idarubicin idoxuridine isotretinoin mitoxantrone hy...	0 Years - 70 Years	Rush University Medical Center
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia	NCT00666588	Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Adult... Recurrent Child... Secondary Acute...	idarubicin cytarabine bortezomib etoposide laboratory biom...	1 Year - 21 Years	National Cancer Institute (NCI)
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT01146210	Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Fanconi Anemia Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child...	laboratory biom...	- 21 Years	Children's Oncology Group
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia	NCT00003178	Leukemia	filgrastim cladribine idarubicin	- 21 Years	Children's Oncology Group
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy	NCT00070174	Leukemia	asparaginase busulfan cyclophosphamid... cyclosporine cytarabine daunorubicin hy... etoposide gemtuzumab ozog... methotrexate mitoxantrone hy... allogeneic bone...	-	Children's Oncology Group
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT00372593	Leukemia	asparaginase cytarabine daunorubicin hy... etoposide gemtuzumab ozog... mitoxantrone hy...	- 29 Years	Children's Oncology Group
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	NCT01132547	Cancer	cyproheptadine ... placebo	2 Years - 21 Years	University of South Florida
DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	NCT00899652	Leukemia	Southern blotti... chromosomal tra... cytogenetic ana... gene rearrangem... mutation analys...	- 21 Years	Children's Oncology Group
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy	NCT00070174	Leukemia	asparaginase busulfan cyclophosphamid... cyclosporine cytarabine daunorubicin hy... etoposide gemtuzumab ozog... methotrexate mitoxantrone hy... allogeneic bone...	-	Children's Oncology Group
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia	NCT00006363	Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... de Novo Myelody... Untreated Adult... Untreated Child...	cytarabine daunorubicin hy... etoposide valspodar filgrastim busulfan autologous hema... peripheral bloo... aldesleukin clinical observ... pharmacological...	15 Years - 59 Years	National Cancer Institute (NCI)
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome	NCT00005593	Leukemia Myelodysplastic...	carboplatin fludarabine pho... topotecan hydro...	12 Years -	Case Comprehensive Cancer Center
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia	NCT01438138	Leukemia	diagnostic labo...	- 21 Years	Children's Oncology Group
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia	NCT01438138	Leukemia	diagnostic labo...	- 21 Years	Children's Oncology Group
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia	NCT00245115	Leukemia	filgrastim busulfan cyclophosphamid... in vitro-treate... in vitro-treate...	- 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia	NCT01076569	Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Child... Untreated Child...	laboratory biom...	- 21 Years	Children's Oncology Group
Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia	NCT01321385	Leukemia	laboratory biom... study of socioe...	- 21 Years	Children's Oncology Group
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome	NCT00005593	Leukemia Myelodysplastic...	carboplatin fludarabine pho... topotecan hydro...	12 Years -	Case Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: